"Navigating the Modern News Zoo so you don't have to."
Sunday, September 7, 2025
Study: Iza-bren and osimertinib combination shows 100% response rate in EGFR-mutated lung cancer
A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
👉 Full Story
2 Popular Stocks Retail Investors Are Buying & What Super Investors Are Doing Now
- Scott Jennings Says This Man Is True Leader Of Democratic Party—And He Isn’t A Dem - Hailey Gomez
- Will the Fed Lower Rates in September? Experts Say Weak Jobs Report ‘Cements’ a Cut
- Elon Musk's Ambitious Plan: To Send One Million Humans to Mars within the Next Decade - Michael A. Medeiros
- Anti-vaccine RFK Jr. creates vaccine panel of anti-vaccine group’s dreams - Beth Mole
- The Evolution and Impact of Internet Jokes: A Closer Look at Prank.Chat - Bertha Stephens
- The Full Moons of 2024: A Comprehensive Guide to Their Names and Dates - Arya Chandran
20 Years of Renting vs. Buying a Home in Canada (2005 to 2024)
- God-Given Rights: The Profoundly Ignorant Tim Kaine - Paul Kengor
- The Right Way to Go After Venezuelan Drug Traffickers - The Editors
- How To Spot Early Signs of Type 2 Diabetes, Plus How To Prevent It - Sherri Gordon
- Imane Khelif Appeals Mandatory Sex Testing, Will Miss Another Competition
- iOS 18 Elevates the iPhone with Unmatched Personalization and Intelligence - Michael A. Medeiros
- Sydney Sweeney's Sexy New Ad Causes More Strange Controversy - Joshua Tyler
